|
gptkbp:instanceOf
|
vaccine
protein subunit vaccine
|
|
gptkbp:activeIngredient
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:adjuvant
|
gptkb:Matrix-M
|
|
gptkbp:administeredBy
|
adolescents
adults
children (in some countries)
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:India
gptkb:Indonesia
gptkb:United_Kingdom
gptkb:United_States
2021-11-17 (Indonesia)
|
|
gptkbp:boosterApprovalDate
|
2022-10-19 (US)
|
|
gptkbp:boosterIndication
|
adults 18 years and older
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:brand
|
gptkb:Covovax
gptkb:Nuvaxovid
|
|
gptkbp:category
|
gptkb:COVID-19_vaccines
protein subunit vaccines
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Mexico
gptkb:South_Africa
gptkb:United_Kingdom
gptkb:United_States
Phase III
|
|
gptkbp:compatibleWith
|
mRNA technology
viral vector technology
|
|
gptkbp:contains
|
gptkb:Matrix-M_adjuvant
recombinant spike protein
|
|
gptkbp:developedBy
|
gptkb:Novavax
|
|
gptkbp:distributor
|
gptkb:Serum_Institute_of_India
gptkb:Biocelect_(Australia)
gptkb:Fujifilm_Diosynth_Biotechnologies_(UK)
gptkb:SK_Bioscience_(South_Korea)
gptkb:Takeda_(Japan)
|
|
gptkbp:dosingSchedule
|
two doses, 3 weeks apart
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
~90% (original strain, clinical trials)
|
|
gptkbp:emergencyServices
|
gptkb:World_Health_Organization
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novavax COVID-19 vaccine
|
|
gptkbp:indication
|
prevention of COVID-19 in individuals 12 years and older
|
|
gptkbp:manufacturer
|
gptkb:Novavax
gptkb:Serum_Institute_of_India_(Covovax)
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
muscle pain
injection site pain
allergic reaction (rare)
|
|
gptkbp:storage
|
2–8°C
standard refrigeration
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
recombinant nanoparticle
|
|
gptkbp:USFDAApprovalDate
|
2022-07-13
|
|
gptkbp:WHOEmergencyUseListing
|
2021-12-17
|
|
gptkbp:bfsParent
|
gptkb:COVID-19
|
|
gptkbp:bfsLayer
|
4
|